

# Yves Pommier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3883762/publications.pdf>

Version: 2024-02-01

257  
papers

29,327  
citations

6233

80  
h-index

5806

161  
g-index

283  
all docs

283  
docs citations

283  
times ranked

28281  
citing authors

#	ARTICLE	IF	CITATIONS
1	Topoisomerase I inhibitors: camptothecins and beyond. <i>Nature Reviews Cancer</i> , 2006, 6, 789-802.	12.8	1,824
2	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. <i>Cancer Research</i> , 2012, 72, 5588-5599.	0.4	1,657
3	DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs. <i>Chemistry and Biology</i> , 2010, 17, 421-433.	6.2	1,507
4	γH2AX and cancer. <i>Nature Reviews Cancer</i> , 2008, 8, 957-967.	12.8	1,423
5	A gene expression database for the molecular pharmacology of cancer. <i>Nature Genetics</i> , 2000, 24, 236-244.	9.4	1,357
6	Drugging Topoisomerases: Lessons and Challenges. <i>ACS Chemical Biology</i> , 2013, 8, 82-95.	1.6	698
7	Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. <i>Nature Reviews Molecular Cell Biology</i> , 2016, 17, 703-721.	16.1	695
8	Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 433-443.	1.9	627
9	Integrase inhibitors to treat HIV/Aids. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 236-248.	21.5	612
10	DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition. <i>Chemical Reviews</i> , 2009, 109, 2894-2902.	23.0	609
11	Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. <i>Oncogene</i> , 2004, 23, 2934-2949.	2.6	524
12	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. <i>Science Translational Medicine</i> , 2016, 8, 362ps17.	5.8	518
13	Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase I-DNA Covalent Complex. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2336-2345.	2.9	447
14	Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. <i>Nature Cell Biology</i> , 2009, 11, 1315-1324.	4.6	445
15	A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. <i>Nature Medicine</i> , 2017, 23, 461-471.	15.2	379
16	Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. <i>Nature Medicine</i> , 2001, 7, 961-966.	15.2	339
17	Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5'-Phosphorylated DNA Double-Strand Breaks by Replication Runoff. <i>Molecular and Cellular Biology</i> , 2000, 20, 3977-3987.	1.1	314
18	Genome Organization Drives Chromosome Fragility. <i>Cell</i> , 2017, 170, 507-521.e18.	13.5	311

#	ARTICLE	IF	CITATIONS
19	DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate <i>Ecteinascidia turbinata</i> . <i>Biochemistry</i> , 1996, 35, 13303-13309.	1.2	288
20	CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. <i>BMC Genomics</i> , 2009, 10, 277.	1.2	273
21	Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). <i>DNA Repair</i> , 2014, 19, 114-129.	1.3	253
22	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15030-15035.	3.3	252
23	Mutagenic Processing of Ribonucleotides in DNA by Yeast Topoisomerase I. <i>Science</i> , 2011, 332, 1561-1564.	6.0	251
24	Repair of Topoisomerase I-mediated DNA Damage. <i>Progress in Molecular Biology and Translational Science</i> , 2006, 81, 179-229.	1.9	247
25	The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology. <i>Cancer Research</i> , 2013, 73, 4372-4382.	0.4	239
26	Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 408-416.	1.3	237
27	Curcumin Analogs with Altered Potencies against HIV-1 Integrase as Probes for Biochemical Mechanisms of Drug Action. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3057-3063.	2.9	228
28	Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. <i>Oncotarget</i> , 2016, 7, 76534-76550.	0.8	219
29	RNA Polymerase II Regulates Topoisomerase I Activity to Favor Efficient Transcription. <i>Cell</i> , 2016, 165, 357-371.	13.5	211
30	Ataxia telangiectasia mutated activation by transcription and topoisomerase I-induced DNA double-strand breaks. <i>EMBO Reports</i> , 2009, 10, 887-893.	2.0	208
31	Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors. <i>Cancer Investigation</i> , 1994, 12, 530-542.	0.6	204
32	Interfacial inhibitors: targeting macromolecular complexes. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 25-36.	21.5	204
33	Targeting Topoisomerase I in the Era of Precision Medicine. <i>Clinical Cancer Research</i> , 2019, 25, 6581-6589.	3.2	184
34	Topoisomerase I-mediated DNA damage. <i>Advances in Cancer Research</i> , 2001, 80, 189-216.	1.9	182
35	Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. <i>Nucleic Acids Research</i> , 1990, 18, 6611-6619.	6.5	179
36	SLFN11 Blocks Stressed Replication Forks Independently of ATR. <i>Molecular Cell</i> , 2018, 69, 371-384.e6.	4.5	177

#	ARTICLE	IF	CITATIONS
37	Quantitative Structure-Antitumor Activity Relationships of Camptothecin Analogues:â€‰ Cluster Analysis and Genetic Algorithm-Based Studies. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3254-3263.	2.9	171
38	Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages. <i>Journal of Biological Chemistry</i> , 1999, 274, 8516-8523.	1.6	168
39	Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I. <i>Journal of Biological Chemistry</i> , 1997, 272, 7792-7796.	1.6	164
40	PARP1â€™TDP1 coupling for the repair of topoisomerase Iâ€™induced DNA damage. <i>Nucleic Acids Research</i> , 2014, 42, 4435-4449.	6.5	163
41	Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 138-145.	4.0	161
42	Topoisomerase I inhibitors: selectivity and cellular resistance. <i>Drug Resistance Updates</i> , 1999, 2, 307-318.	6.5	158
43	Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Repairs DNA Damage Induced by Topoisomerases I and II and Base Alkylation in Vertebrate Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 12848-12857.	1.6	155
44	Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps. <i>Journal of Biological Chemistry</i> , 1997, 272, 26441-26447.	1.6	153
45	The Novel Silatecan 7-tert-Butyldimethylsilyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3970-3980.	2.9	147
46	Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity. <i>Molecular Cell</i> , 2019, 75, 252-266.e8.	4.5	145
47	The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1008-1014.	1.9	144
48	Ion Selective Folding of Loop Domains in a Potent Anti-HIV Oligonucleotideâ€™. <i>Biochemistry</i> , 1997, 36, 12498-12505.	1.2	139
49	Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase Iâ€™DNA complexes. <i>Journal of Cell Biology</i> , 2011, 195, 739-749.	2.3	138
50	Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amacrine or teniposide. <i>Nucleic Acids Research</i> , 1991, 19, 5973-5980.	6.5	136
51	Production of Extrachromosomal MicroDNAs Is Linked to Mismatch Repair Pathways and Transcriptional Activity. <i>Cell Reports</i> , 2015, 11, 1749-1759.	2.9	135
52	Tyrosyl-DNA Phosphodiesterase as a Target for Anticancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 381-389.	0.9	133
53	Poly(ADP-ribose) polymerase and XPFâ€™ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. <i>Nucleic Acids Research</i> , 2011, 39, 3607-3620.	6.5	132
54	ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses. <i>Cancer Research</i> , 2014, 74, 6968-6979.	0.4	131

#	ARTICLE	IF	CITATIONS
55	MGMT Status as a Clinical Biomarker in Glioblastoma. <i>Trends in Cancer</i> , 2020, 6, 380-391.	3.8	131
56	Mechanisms of Camptothecin Resistance by Human Topoisomerase I Mutations. <i>Journal of Molecular Biology</i> , 2004, 339, 773-784.	2.0	129
57	Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. <i>EMBO Journal</i> , 2009, 28, 3667-3680.	3.5	125
58	Human topoisomerases and their roles in genome stability and organization. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 407-427.	16.1	125
59	Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19790-19795.	3.3	124
60	Synthesis of Cytotoxic Indenoisoquinoline Topoisomerase I Poisons. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 446-457.	2.9	122
61	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. <i>Oncotarget</i> , 2016, 7, 3084-3097.	0.8	120
62	Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. <i>Nucleic Acids Research</i> , 2002, 30, 1198-1204.	6.5	119
63	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. <i>IScience</i> , 2018, 10, 247-264.	1.9	117
64	Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response. <i>Journal of Biological Chemistry</i> , 2009, 284, 18085-18095.	1.6	116
65	Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 214-220.	1.9	116
66	Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. , 1999, 82, 396-404.		111
67	Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks. <i>Cell Reports</i> , 2019, 28, 3167-3181.e6.	2.9	108
68	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021, 39, 566-579.e7.	7.7	107
69	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. , 2019, 201, 94-102.		106
70	Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2-DNA and Top2-RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2). <i>Journal of Biological Chemistry</i> , 2014, 289, 17960-17969.	1.6	103
71	Synthesis and Mechanism of Action Studies of a Series of Norindenoisoquinoline Topoisomerase I Poisons Reveal an Inhibitor with a Flipped Orientation in the Ternary DNA-Enzyme-Inhibitor Complex As Determined by X-ray Crystallographic Analysis. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4803-4814.	2.9	102
72	Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity. <i>Clinical Cancer Research</i> , 2014, 20, 4873-4881.	3.2	102

#	ARTICLE	IF	CITATIONS
73	Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic Analyses. <i>Cancer Research</i> , 2007, 67, 8752-8761.	0.4	93
74	Mitochondrial Topoisomerase I is Critical for Mitochondrial Integrity and Cellular Energy Metabolism. <i>PLoS ONE</i> , 2012, 7, e41094.	1.1	93
75	DNA cleavage assay for the identification of topoisomerase I inhibitors. <i>Nature Protocols</i> , 2008, 3, 1736-1750.	5.5	92
76	Temozolomide in the Era of Precision Medicine. <i>Cancer Research</i> , 2017, 77, 823-826.	0.4	91
77	<i>SLFN11</i> Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 4184-4193.	3.2	89
78	Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2004, 4, 429-434.	7.0	87
79	TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. <i>Nucleic Acids Research</i> , 2012, 40, 8371-8380.	6.5	86
80	TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. <i>Nucleic Acids Research</i> , 2013, 41, 7793-7803.	6.5	86
81	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. <i>Cell Reports</i> , 2020, 33, 108296.	2.9	86
82	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	86
83	Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)-Topoisomerase I (Top1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4457-4478.	2.9	85
84	Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. <i>Clinical Cancer Research</i> , 2002, 8, 2499-504.	3.2	82
85	Genomic and evolutionary classification of lung cancer in never smokers. <i>Nature Genetics</i> , 2021, 53, 1348-1359.	9.4	81
86	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. <i>Oncogene</i> , 2001, 20, 1852-1859.	2.6	80
87	Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. <i>Clinical Cancer Research</i> , 2015, 21, 3841-3852.	3.2	80
88	Apoptosis Induced by DNA Topoisomerase I and II Inhibitors in Human Leukemic HL-60 Cells. <i>Leukemia and Lymphoma</i> , 1994, 15, 21-32.	0.6	78
89	Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 2657-2661.	3.2	78
90	Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 1285-1292.	2.4	78

#	ARTICLE	IF	CITATIONS
91	A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation. <i>Science Advances</i> , 2020, 6, .	4.7	76
92	Gene Expression Correlations in Human Cancer Cell Lines Define Molecular Interaction Networks for Epithelial Phenotype. <i>PLoS ONE</i> , 2014, 9, e99269.	1.1	76
93	Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. <i>PLoS ONE</i> , 2017, 12, e0171582.	1.1	72
94	8-Oxoguanine rearranges the active site of human topoisomerase I. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12102-12107.	3.3	68
95	Increased negative supercoiling of mtDNA in TOP1mt knockout mice and presence of topoisomerases II $\hat{A}$ and II $\hat{A}$ in vertebrate mitochondria. <i>Nucleic Acids Research</i> , 2014, 42, 7259-7267.	6.5	67
96	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. <i>Nature Cell Biology</i> , 2022, 24, 62-73.	4.6	66
97	Interfacial Inhibitors of Protein-Nucleic Acid Interactions. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2005, 5, 421-429.	7.0	65
98	Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( <i>SLFN11</i> ) Expression with Class I Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1944-1953.	3.2	65
99	Molecular and Biological Determinants of the Cytotoxic Actions of Camptothecins: Perspective for the Development of New Topoisomerase I Inhibitors. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 11-26.	1.8	64
100	RNA topoisomerase is prevalent in all domains of life and associates with polyribosomes in animals. <i>Nucleic Acids Research</i> , 2016, 44, 6335-6349.	6.5	63
101	Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. <i>FEBS Letters</i> , 2001, 505, 7-12.	1.3	62
102	Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC). <i>DNA Repair</i> , 2020, 89, 102837.	1.3	62
103	Topoisomerase I-mediated cleavage at unrepaired ribonucleotides generates DNA double-strand breaks. <i>EMBO Journal</i> , 2017, 36, 361-373.	3.5	59
104	Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1431-1441.	1.9	58
105	Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 433-438.	1.1	57
106	Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase in reconstituted Simian virus 40 chromatin. <i>Nucleic Acids Research</i> , 1990, 18, 4553-4559.	6.5	56
107	Poisoning of Mitochondrial Topoisomerase I by Lamellarin D. <i>Molecular Pharmacology</i> , 2014, 86, 193-199.	1.0	56
108	Hyperphosphorylation of RNA Polymerase II in Response to Topoisomerase I Cleavage Complexes and Its Association with Transcription- and BRCA1-dependent Degradation of Topoisomerase I. <i>Journal of Molecular Biology</i> , 2008, 381, 540-549.	2.0	55

#	ARTICLE	IF	CITATIONS
109	Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. <i>DNA Repair</i> , 2015, 28, 107-115.	1.3	55
110	Multiview confocal super-resolution microscopy. <i>Nature</i> , 2021, 600, 279-284.	13.7	55
111	Biochemical Characterization of Human Tyrosyl-DNA Phosphodiesterase 2 (TDP2/TTRAP). <i>Journal of Biological Chemistry</i> , 2012, 287, 30842-30852.	1.6	54
112	Structural basis for recognition of 5â€²-phosphotyrosine adducts by Tdp2. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 1372-1377.	3.6	53
113	Topoisomerase I Alone Is Sufficient to Produce Short DNA Deletions and Can Also Reverse Nicks at Ribonucleotide Sites. <i>Journal of Biological Chemistry</i> , 2015, 290, 14068-14076.	1.6	52
114	Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2734-2746.	2.9	52
115	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 843-859.	0.5	51
116	Synthesis and Biological Evaluation of Nitrated 7-, 8-, 9-, and 10-Hydroxyindenoisoquinolines as Potential Dual Topoisomerase I (Top1)â€™Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3188-3208.	2.9	50
117	Lack of mitochondrial topoisomerase I ( <i>TOP1mt</i> ) impairs liver regeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11282-11287.	3.3	50
118	The NCI-60 Methylome and Its Integration into CellMiner. <i>Cancer Research</i> , 2017, 77, 601-612.	0.4	48
119	Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways. <i>DNA Repair</i> , 2020, 94, 102926.	1.3	48
120	Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress. <i>Cell Reports</i> , 2020, 30, 4137-4151.e6.	2.9	48
121	DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. <i>Mutation Research DNA Repair</i> , 1995, 337, 135-145.	3.8	47
122	DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. <i>Cell Cycle</i> , 2010, 9, 274-278.	1.3	47
123	A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16125-16130.	3.3	47
124	The evolving landscape of predictive biomarkers of response to PARP inhibitors. <i>Journal of Clinical Investigation</i> , 2018, 128, 1727-1730.	3.9	47
125	Relative contribution of four nucleases, CtIP, Dna2, Exo1 and Mre11, to the initial step of DNA double-strand break repair by homologous recombination in both the chicken DT40 and human TK6 cell lines. <i>Genes To Cells</i> , 2015, 20, 1059-1076.	0.5	46
126	Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7315-7332.	2.9	44



#	ARTICLE	IF	CITATIONS
127	Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3275-3288.	2.9	43
128	Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4890-4899.	2.9	42
129	Structural Impact of the Leukemia Drug 1- $\beta$ -D-Arabinofuranosylcytosine (Ara-C) on the Covalent Human Topoisomerase I-DNA Complex. <i>Journal of Biological Chemistry</i> , 2003, 278, 12461-12466.	1.6	41
130	Discovery of Potent Indenoisoquinoline Topoisomerase I Poisons Lacking the 3-Nitro Toxicophore. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3997-4015.	2.9	40
131	Small cell lung cancer: Time to revisit DNA-damaging chemotherapy. <i>Science Translational Medicine</i> , 2016, 8, 346fs12.	5.8	40
132	PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes. <i>Nucleic Acids Research</i> , 2018, 46, 5601-5617.	6.5	40
133	BAMscale: quantification of next-generation sequencing peaks and generation of scaled coverage tracks. <i>Epigenetics and Chromatin</i> , 2020, 13, 21.	1.8	40
134	rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R. <i>Bioinformatics</i> , 2016, 32, 1272-1274.	1.8	39
135	<i>N</i> -Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4610-4623.	2.9	38
136	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. <i>Oncotarget</i> , 2016, 7, 13269-13284.	0.8	38
137	Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I. <i>Nucleic Acids Research</i> , 2013, 41, 9848-9857.	6.5	37
138	Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9908-9930.	2.9	37
139	Different Effects on Human Topoisomerase I by Minor Groove and Intercalated Deoxyguanosine Adducts Derived from Two Polycyclic Aromatic Hydrocarbon Diol Epoxides at or Near a Normal Cleavage Site. <i>Journal of Biological Chemistry</i> , 2002, 277, 13666-13672.	1.6	36
140	NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 5830-5840.	3.2	36
141	High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner. <i>PLoS ONE</i> , 2014, 9, e92047.	1.1	36
142	Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate. <i>Journal of Biological Chemistry</i> , 2000, 275, 15246-15253.	1.6	35
143	Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3840-3853.	2.9	35
144	HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. <i>ACS Chemical Biology</i> , 2016, 11, 1074-1081.	1.6	35

#	ARTICLE	IF	CITATIONS
145	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. <i>Oncogene</i> , 2019, 38, 180-193.	2.6	35
146	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
147	Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. <i>Nucleic Acids Research</i> , 1999, 27, 1919-1925.	6.5	34
148	Thirteen-exon-motif signature for vertebrate nuclear and mitochondrial type IB topoisomerases. <i>Nucleic Acids Research</i> , 2004, 32, 2087-2092.	6.5	34
149	Interfacial inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3961-3965.	1.0	34
150	The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. <i>Clinical Cancer Research</i> , 2019, 25, 6206-6216.	3.2	34
151	ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. <i>PLoS ONE</i> , 2017, 12, e0188320.	1.1	34
152	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 73-81.	1.1	32
153	Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. <i>ACS Chemical Biology</i> , 2016, 11, 1925-1933.	1.6	32
154	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1694-1704.	1.9	30
155	SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	30
156	Analogues of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. <i>Oncotarget</i> , 2016, 7, 13984-14001.	0.8	30
157	Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5364-5376.	2.9	29
158	Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. <i>Drug Development Research</i> , 1995, 34, 138-144.	1.4	28
159	Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. <i>DNA Repair</i> , 2014, 13, 1-9.	1.3	28
160	Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2116-2126.	3.2	28
161	Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in silencing the dormant Ube3a gene associated with Angelman syndrome. <i>Molecular Autism</i> , 2018, 9, 45.	2.6	28
162	Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. <i>Oncogene</i> , 2020, 39, 5520-5535.	2.6	28

#	ARTICLE	IF	CITATIONS
163	Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. <i>Nucleic Acids Research</i> , 2019, 47, 10134-10150.	6.5	27
164	DNA and RNA Cleavage Complexes and Repair Pathway for TOP3B RNA- and DNA-Protein Crosslinks. <i>Cell Reports</i> , 2020, 33, 108569.	2.9	27
165	Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. <i>Pharmaceutical Research</i> , 1996, 13, 1892-1895.	1.7	26
166	How Do Drug-Induced Topoisomerase I-DNA Lesions Signal to the Molecular Interaction Network that Regulates Cell Cycle Checkpoints, DNA Replication, and DNA Repair?. <i>Cell Biochemistry and Biophysics</i> , 2000, 33, 175-180.	0.9	26
167	PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation. <i>Nature Communications</i> , 2021, 12, 5010.	5.8	26
168	In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. <i>Nucleic Acids Research</i> , 1997, 25, 4111-4116.	6.5	25
169	Mapping Topoisomerase Sites in Mitochondrial DNA with a Poisonous Mitochondrial Topoisomerase I (Top1mt). <i>Journal of Biological Chemistry</i> , 2014, 289, 18595-18602.	1.6	25
170	TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2543-2551.	1.9	25
171	Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 569-579.	1.4	25
172	Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113261.	2.6	24
173	The dominant role of proofreading exonuclease activity of replicative polymerase $\delta$ in cellular tolerance to cytarabine (Ara-C). <i>Oncotarget</i> , 2017, 8, 33457-33474.	0.8	24
174	Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 56.	3.5	23
175	SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. <i>Cancer Research</i> , 2021, 81, 3067-3078.	0.4	23
176	Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. <i>Nucleic Acids Research</i> , 2011, 39, 6620-6632.	6.5	22
177	Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1469-1479.	1.4	22
178	Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. <i>Frontiers in Oncology</i> , 2019, 9, 994.	1.3	22
179	Cellular Resistance to Camptothecins. <i>Annals of the New York Academy of Sciences</i> , 1996, 803, 60-73.	1.8	21
180	Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. <i>DNA Repair</i> , 2014, 21, 177-182.	1.3	21

#	ARTICLE	IF	CITATIONS
181	The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. <i>BMC Cancer</i> , 2020, 20, 1123.	1.1	21
182	Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition. <i>Biochemical Journal</i> , 2008, 411, 523-530.	1.7	20
183	Biological evaluation of imidazolium- and ammonium-based salts as HIV-1 integrase inhibitors. <i>MedChemComm</i> , 2011, 2, 143-150.	3.5	20
184	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. <i>PLoS ONE</i> , 2021, 16, e0237554.	1.1	20
185	Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. <i>ACS Chemical Biology</i> , 2016, 11, 2996-3001.	1.6	19
186	Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its short isoform. <i>EMBO Reports</i> , 2018, 19, .	2.0	19
187	An interplay of NOX1-derived ROS and oxygen determines the spermatogonial stem cell self-renewal efficiency under hypoxia. <i>Genes and Development</i> , 2021, 35, 250-260.	2.7	19
188	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. <i>Cancers</i> , 2021, 13, 4601.	1.7	19
189	Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins. <i>Oncotarget</i> , 2018, 9, 37286-37288.	0.8	19
190	Resolution of R-loops by topoisomerase III- $\beta^2$ (TOP3B) in coordination with the DEAD-box helicase DDX5. <i>Cell Reports</i> , 2022, 40, 111067.	2.9	19
191	Biochemical Assays for the Discovery of TDP1 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2116-2126.	1.9	18
192	Chromatin Regulators as a Guide for Cancer Treatment Choice. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1768-1777.	1.9	18
193	DNA-Targeted Precision Medicine; Have We Been Caught Sleeping?. <i>Trends in Cancer</i> , 2017, 3, 2-6.	3.8	18
194	Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites. <i>Chemical Science</i> , 2021, 12, 3876-3884.	3.7	18
195	A polymer index-matched to water enables diverse applications in fluorescence microscopy. <i>Lab on A Chip</i> , 2021, 21, 1549-1562.	3.1	18
196	Novel TDP2-ubiquitin interactions and their importance for the repair of topoisomerase II-mediated DNA damage. <i>Nucleic Acids Research</i> , 2016, 44, gkw719.	6.5	17
197	Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription. <i>Journal of Biological Chemistry</i> , 2017, 292, 20162-20172.	1.6	17
198	Structural, molecular, and functional insights into Schlafen proteins. <i>Experimental and Molecular Medicine</i> , 2022, 54, 730-738.	3.2	17

#	ARTICLE	IF	CITATIONS
199	Neuroprotection and repair of 3'-blocking DNA ends by glaikit (gkt) encoding Drosophila tyrosyl-DNA phosphodiesterase 1 (TDP1). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15816-15820.	3.3	16
200	Selectivity for strand-transfer over 3' processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site. Nucleic Acids Research, 2016, 44, 6896-6906.	6.5	16
201	Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14412-14420.	3.3	16
202	Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes. Nucleic Acids Research, 2021, 49, 10493-10506.	6.5	16
203	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. International Journal of Cancer, 1994, 58, 85-94.	2.3	15
204	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. Marine Drugs, 2015, 13, 3625-3639.	2.2	15
205	Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. European Journal of Medicinal Chemistry, 2015, 101, 525-533.	2.6	15
206	Parallel analysis of ribonucleotide-dependent deletions produced by yeast Top1 in vitro and in vivo. Nucleic Acids Research, 2016, 44, 7714-7721.	6.5	15
207	TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining. Nucleic Acids Research, 2018, 46, 8926-8939.	6.5	15
208	Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. DNA Repair, 2020, 85, 102747.	1.3	15
209	2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 355-378.	2.5	15
210	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. International Journal of Cancer, 1995, 63, 268-275.	2.3	14
211	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). European Journal of Pharmaceutical Sciences, 2018, 118, 67-79.	1.9	14
212	Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ <i>a</i> ]pyrrolo[2,3- <i>h</i> ][1,6]naphthyridin-5-one (BPN) Series. Journal of Medicinal Chemistry, 2018, 61, 10440-10462.	2.9	14
213	Synthesis of Methoxy-, Methylendioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. Journal of Medicinal Chemistry, 2021, 64, 7617-7629.	2.9	14
214	Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors. Molecular Cancer Therapeutics, 2015, 14, 2552-2559.	1.9	13
215	HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia. Scientific Reports, 2017, 7, 12849.	1.6	13
216	Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides. European Journal of Pharmaceutical Sciences, 2018, 111, 337-348.	1.9	13

#	ARTICLE	IF	CITATIONS
217	Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4669-4682.	2.9	13
218	TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1090-1102.	1.9	13
219	Distribution bias and biochemical characterization of TOP1MT single nucleotide variants. <i>Scientific Reports</i> , 2017, 7, 8614.	1.6	12
220	Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1). <i>SLAS Discovery</i> , 2017, 22, 1093-1105.	1.4	12
221	Endogenous single-strand DNA breaks at RNA polymerase II promoters in <i>Saccharomyces cerevisiae</i> . <i>Nucleic Acids Research</i> , 2018, 46, 10649-10668.	6.5	12
222	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. <i>Cancer Research Communications</i> , 2022, 2, 503-517.	0.7	12
223	Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 409-416.	1.1	11
224	Beyond the unwinding: role of TOP1MT in mitochondrial translation. <i>Cell Cycle</i> , 2019, 18, 2377-2384.	1.3	11
225	Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 81-92.	2.6	11
226	Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states. <i>Nature Communications</i> , 2022, 13, 59.	5.8	11
227	Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers. <i>European Journal of Medicinal Chemistry</i> , 2015, 106, 132-143.	2.6	10
228	F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. <i>Future Oncology</i> , 2016, 12, 2183-2188.	1.1	10
229	The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1589-1597.	1.9	10
230	Early Induction of Apoptosis in Hematopoietic Cell Lines After Exposure to Flavopiridol. <i>Blood</i> , 1998, 91, 458-465.	0.6	10
231	Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy. <i>Cancer Science</i> , 2022, 113, 784-795.	1.7	10
232	Effects of camptothecin or TOP1 overexpression on genetic stability in <i>Saccharomyces cerevisiae</i> . <i>DNA Repair</i> , 2017, 59, 69-75.	1.3	9
233	Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor. <i>Molecular Cancer Research</i> , 2021, 19, 1338-1349.	1.5	9
234	DNA Topoisomerases and Their Inhibition by Anthracyclines. <i>ACS Symposium Series</i> , 1994, , 183-203.	0.5	8

#	ARTICLE	IF	CITATIONS
235	Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I. <i>Journal of the American Chemical Society</i> , 2020, 142, 21178-21188.	6.6	7
236	SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 871161.	1.6	7
237	Virtual screening using ligand-based pharmacophores for inhibitors of human tyrosyl-DNA phosphodiesterase (hTdp1). <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2347-2355.	1.4	6
238	Mammalian Tyrosyl-DNA Phosphodiesterases in the Context of Mitochondrial DNA Repair. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3015.	1.8	6
239	Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes. <i>Science Advances</i> , 2021, 7, .	4.7	6
240	Schlafen 11 Expression in Human Acute Leukemia Cells with Gain-of-Function Mutations in the Interferon-JAK Signaling Pathway. <i>IScience</i> , 2021, 24, 103173.	1.9	6
241	Mutations in the HIV Type 1 Integrase of Patients Receiving Long-Term Dideoxynucleoside Therapy Do Not Confer Resistance to Zidovudine. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1417-1422.	0.5	5
242	<i>topIb</i> , a phylogenetic hallmark gene of Thaumarchaeota encodes a functional eukaryote-like topoisomerase IB. <i>Nucleic Acids Research</i> , 2016, 44, 2795-2805.	6.5	5
243	Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening. <i>Molecules</i> , 2019, 24, 3675.	1.7	5
244	The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 818-822.	2.5	5
245	Design and synthesis of C-aryl angular luotonins via a one-pot aza-Nazarovâ€Friedlander sequence and their Topo-I inhibition studies along with C-aryl vasicinones and luotonins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 41, 127998.	1.0	5
246	From Antarctica to cancer research: a novel human DNA topoisomerase IB inhibitor from Antarctic sponge <i>Dendrilla antarctica</i> . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1404-1410.	2.5	5
247	Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3â€²- and 5â€²-phosphodiester-DNA bond cleavage. <i>DNA Repair</i> , 2018, 66-67, 64-71.	1.3	4
248	Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity. <i>Bioorganic Chemistry</i> , 2022, 123, 105789.	2.0	4
249	HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence. <i>Molecules</i> , 2018, 23, 1858.	1.7	3
250	Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1. <i>Cancer Research</i> , 2019, 79, 2460-2461.	0.4	3
251	CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1430-1438.	1.9	3
252	Novel screen for anti-cancer drugs that elevate chromosome instability (CIN) using human artificial chromosome (HAC). <i>Oncotarget</i> , 2018, 9, 36833-36835.	0.8	2

#	ARTICLE	IF	CITATIONS
253	Cancer/Testis Antigen 55 is required for cancer cell proliferation and mitochondrial DNA maintenance. <i>Mitochondrion</i> , 2022, 64, 19-26.	1.6	2
254	Bay-Region Diol Epoxides of Benzo[a]Pyrene are Stealth Poisons of Topoisomerase I. <i>Polycyclic Aromatic Compounds</i> , 2000, 21, 53-62.	1.4	0
255	Response to Letter to the Editor by Yang etÂal.. <i>Journal of Thoracic Oncology</i> , 2020, 15, e91.	0.5	0
256	Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 727836.	1.8	0
257	Topoisomeraseâ€Induced DNA Cleavage at Ribonucleotide Misincorporation Sites. <i>FASEB Journal</i> , 2015, 29, 371.3.	0.2	0